Want to see IN:HALEOSLABS full AI Analyst Report?

SMS Lifesciences India Ltd. (HALEOSLABS) Price & Analysis

1 Followers

HALEOSLABS Stock Chart & Stats

₹1105.00

₹4.55(0.36%)

At close: Jan 08 4:00 PM EST

₹1105.00

₹4.55(0.36%)

Day’s Range― - ―

52-Week Range₹1,100.60 - ₹1,778.35

Previous CloseN/A

VolumeN/A

Average Volume (3M)68.00

Market Cap

₹4.71B

Enterprise Value₹4.87B

Total Cash (Recent Filing)₹11.92M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)28.7

Beta1.15

Next Earnings

Nov 16, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.1%

Share Statistics

EPS (TTM)48.10

Shares Outstanding3,023,287

10 Day Avg. Volume112

30 Day Avg. Volume68

Financial Highlights & Ratios

PEG Ratio-1.50

Price to Book (P/B)1.69

Price to Sales (P/S)1.08

P/FCF Ratio-15.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

FY2026 Revenue ReboundThe strong FY2026 revenue rebound indicates improving demand for the company’s API and intermediate products after a mixed prior growth pattern. If sustained, higher sales can improve capacity utilization, strengthen customer relationships, and provide a broader base for future earnings recovery.

Manageable Leverage And Growing EquityModerate leverage and steady equity growth provide a reasonably supportive capital base for an API manufacturer. Although debt has increased, the current balance-sheet structure retains financial flexibility and gives the company a foundation to fund operations and selective investment.

Established API Market ReachParticipation across domestic and export API markets gives SMS Lifesciences multiple channels through which to sell pharma-grade compounds. Serving formulation companies also places the business within an established medicines supply chain, supporting ongoing relevance beyond any single product or customer.

Bears Say

Sharp Gross Margin CompressionThe severe gross-margin decline shows that the recent revenue rebound has not translated proportionately into profitable growth. Persistent pricing pressure, product-mix effects, or higher production costs could limit earnings recovery and reduce the funds available for reinvestment in the business.

Weak Cash Conversion And Negative Free Cash FlowLow operating-cash-flow coverage indicates that reported earnings are converting weakly into cash, while the move to materially negative free cash flow raises funding needs. If this pattern persists, growth may rely more heavily on debt or equity rather than internally generated resources.

Rising Debt And Modest ReturnsIncreasing debt alongside declining returns on equity points to less efficient use of capital and greater sensitivity to continued margin pressure. Even with leverage still described as moderate, weaker profitability could make future borrowing less productive and constrain capital-allocation flexibility.

SMS Lifesciences India Ltd. News

Haleos Labs Confirms All Resolutions Passed at 20th AGM Held Online

SMS Lifesciences India Ltd. ( ($IN:HALEOSLABS) ) has provided an update. Haleos Labs Limited has reported the voting...

25d ago

Haleos Labs’ Mahi Drugs Unit Clears USFDA Inspection with No Observations

An update from SMS Lifesciences India Ltd. ( ($IN:HALEOSLABS) ) is now available. Haleos Labs Limited announced that...

1M ago

Haleos Labs Sets 20th AGM to Approve FY26 Results, Dividend and New Auditor

SMS Lifesciences India Ltd. ( ($IN:HALEOSLABS) ) has shared an announcement. Haleos Labs Limited has convened its 20th...

2M ago

Haleos Labs Publishes Notices for 20th AGM in Line with SEBI Norms

SMS Lifesciences India Ltd. ( ($IN:HALEOSLABS) ) has provided an announcement. Haleos Labs Limited, formerly SMS Lifesciences India...

2M ago

HALEOSLABS FAQ

What was SMS Lifesciences India Ltd.’s price range in the past 12 months?

SMS Lifesciences India Ltd. lowest stock price was ₹1100.60 and its highest was ₹1778.35 in the past 12 months.

What is SMS Lifesciences India Ltd.’s market cap?

SMS Lifesciences India Ltd.’s market cap is ₹4.71B.

When is SMS Lifesciences India Ltd.’s upcoming earnings report date?

SMS Lifesciences India Ltd.’s upcoming earnings report date is Nov 16, 2026 which is in 21 days.

How were SMS Lifesciences India Ltd.’s earnings last quarter?

SMS Lifesciences India Ltd. released its earnings results on Aug 05, 2026. The company reported ₹8.754 earnings per share for the quarter.

Is SMS Lifesciences India Ltd. overvalued?

According to Wall Street analysts SMS Lifesciences India Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does SMS Lifesciences India Ltd. pay dividends?

SMS Lifesciences India Ltd. pays a Annually dividend of ₹1.5 which represents an annual dividend yield of 0.1%. See more information on SMS Lifesciences India Ltd. dividends here

What is SMS Lifesciences India Ltd.’s EPS estimate?

SMS Lifesciences India Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SMS Lifesciences India Ltd. have?

SMS Lifesciences India Ltd. has 3,023,287 shares outstanding.

What happened to SMS Lifesciences India Ltd.’s price movement after its last earnings report?

SMS Lifesciences India Ltd. reported an EPS of ₹8.754 in its last earnings report. Following the earnings report the stock price went down -10.178%.

Which hedge fund is a major shareholder of SMS Lifesciences India Ltd.?

Currently, no hedge funds are holding shares in IN:HALEOSLABS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SMS Lifesciences India Ltd.

Haleos Labs Limited, an Indian-based pharmaceutical enterprise, specializes in the production of crucial active pharmaceutical ingredients (APIs) and intermediate compounds. Their extensive portfolio encompasses a wide array of therapeutic applications, providing treatments for conditions such as ulcers, migraines, hypertension, and erectile dysfunction. Additionally, the company develops products for cancer, fungal infections, obesity, nausea, depression, parasitic infestations, various infectious diseases, gout, convulsions, viral ailments, and anesthesia. They also supply ingredients for antihistamines, diuretics, hair loss treatments, and ophthalmic preparations. A significant portion of their manufactured goods is destined for international markets. Established in 1990 and headquartered in Hyderabad, India, the firm was formerly known as SMS Lifesciences India Limited and is scheduled to officially adopt its current name, Haleos Labs Limited, in August 2025.